EEG microstates

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Retrieved on: 
Tuesday, November 7, 2023
Telecanthus, EEG microstates, Trial of the century, OMNI, LCD, WPS, Ophthalmology, Medicare, MIGS, Macs, Congress, IOP, Publication, GAAP, Nature, Environment, News, Growth, Cataract, Clinical trial, Surgeon, American Academy, Webcast, London, Refraction, European Society of Clinical Microbiology and Infectious Diseases, Centers for Medicare & Medicaid Services, Patient, GEMINI, Pharmaceutical industry, Video game, Ciclosporin

Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.

Key Points: 
  • Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.
  • Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the prior year.
  • On October 26, 2023, WPS Government Health Administrators (“WPS”), a Medicare Administrative Contractor (“MAC”), published an LCD with an effective date of December 24, 2023.
  • Sight Sciences' management team will host a conference call today, November 7, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023

Retrieved on: 
Monday, October 30, 2023
Health, Surgery, Health Technology, Practice Management, Pharmaceutical, Optical, American Academy of Ophthalmology, Virtual reality, EEG microstates, NYSE, Eye, Phacoemulsification, Anatomical terms of location, Femtosecond, Cataract surgery, Equity, AAO, Bachelor of Science, Intraocular lens, Quality of life, Conference, Data, Participation, Instrument, Corniche (Abu Dhabi), Palace Hotel, American Academy, Surgeon, Ecosystem, Comparison, Quality, Zimmer Biomet Robotics, OCT, Patient, High, Lock (computer science), Physiology, Cataract, Nursing, Medical device, Ophthalmology, MD, IOL, LASIK, Alcon, Retina

Ophthalmologists, surgical staff, researchers, and industry leaders will have the opportunity to experience Alcon’s latest digital offerings and participate in additional Alcon events during the conference.

Key Points: 
  • Ophthalmologists, surgical staff, researchers, and industry leaders will have the opportunity to experience Alcon’s latest digital offerings and participate in additional Alcon events during the conference.
  • Alcon AAO event information and registration is available at MyAlconatAAO.com .
  • With the full, U.S. commercial availability of SMARTCataract, Alcon furthers its position as a leader in surgical ophthalmology.
  • For more information about the Alcon products and services on display at AAO, please visit MyAlconatAAO.com .

Alcon Announces Largest-Ever Scientific Presence at ASCRS 2023 and Expands Image-Guided Connectivity

Retrieved on: 
Monday, May 1, 2023
Research, Pharmaceutical, Optical, Medical Devices, Clinical Trials, Science, Surgery, Biotechnology, Medical Supplies, Other Science, Health, Diabetes, Ophthalmology, ASCRS, Zimmer Biomet Robotics, Patient, OCT, Randomized controlled trial, News, NYSE, Glaucoma, Trifocal lenses, Capsulorhexis, Electronic, Intraocular pressure, EEG microstates, Cataract, Cataract surgery, Refractive surgery, SENTRY, American Society of Cataract and Refractive Surgery, Phacoemulsification, Intraocular lens, Micheletti, IOP, Surgeon, ABO, Vision system, Refraction, Trial of the century, Annual general meeting, IOL, Society, Veterinary medicine, Telescopic sight, Medical device, Dentistry, Alcon, MD

Alcon ASCRS event information and registration is available at MyAlconatASCRS.com .

Key Points: 
  • Alcon ASCRS event information and registration is available at MyAlconatASCRS.com .
  • “The pace of innovation happening across eye care is extraordinary, and as the industry leader, we are excited to be leading the charge at ASCRS 2023,” said Sergio Duplan, President, North America at Alcon.
  • evaluates a head-to-head comparison of distance and intermediate vision of Clareon monofocal IOL and TECNIS Eyhance* monofocal IOL.
  • For information on Alcon events and news at ASCRS, please visit MyAlconatASCRS.com .

Florida’s Palm Vascular Centers is the First Healthcare Organization to Install XenFI, the Recently Announced Wireless Medical Ecosystem from Xenter

Retrieved on: 
Wednesday, November 2, 2022
Technology, Mobile, Wireless, Health Technology, Software, Networks, Other Health, Internet, Health, Data Management, Info, Interventions, MD, Publication, CEO, Partnership, Joe Byrd (Cherokee Nation Principal Chief), Clinical trial, Moyamoya disease, Beasley, Documentation, Organization, ML, NIH, Amputation, Physician, Industry, Mount Sinai Medical Center, Ecosystem, Wilford Hall Ambulatory Surgical Center, CLI, University, PAD, Medicare, Theory of multiple intelligences, XMD, Sudarshan K. Aggarwal, Patient, Artificial intelligence, Machine learning, Aneurysm, Multimedia, 3D ultrasound, National, EEG microstates, Mount Sinai Medical Center (Miami), Society, Wake Forest School of Medicine, Jacqueline Oble, Pharmaceutical industry, Medical device, Medicine, Medical imaging

The author of numerous publications in peer-reviewed medical journals, his work has been presented at more than 100 regional, national, and international medical meetings.

Key Points: 
  • The author of numerous publications in peer-reviewed medical journals, his work has been presented at more than 100 regional, national, and international medical meetings.
  • Palm Vascular treats a myriad of vascular conditions today and is the first vascular lab in South Florida with locations in multiple counties.
  • Xenter has launched a wireless Technology in Medicine (TechMed) ecosystem designed to provide transformative outcomes for physicians, healthcare professionals, provider organizations, and patients.
  • Xenter, XenFI, XMD, and Physical Intelligence are trademarks, of Xenter, Inc. All other trademarks and copyrights are property of their respective owners.

Iantrek Raises $23M Series B Financing to Advance Next Generation Ophthalmic Micro-Interventional Technologies

Retrieved on: 
Tuesday, August 30, 2022
Icahn School of Medicine at Mount Sinai, CEO, Technology, Ginger, Ivanti, Lists of people executed in the United States, American Academy, EEG microstates, Severe cognitive impairment, Board, CFA, LinkedIn, IOP, Mount Sinai, Investment, Glaucoma, GLOBE, MIGS, Board of directors, CAGR, FDA, American Academy of Ophthalmology, Marketing, Industry, Acquisition, General partnership, Patient, Medical device, Medicine, Ophthalmology

WHITE PLAINS, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing.

Key Points: 
  • WHITE PLAINS, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing.
  • Iantrek is the only MIGS company with FDA-registered technologies designed to address both natural aqueous outflow pathways, trabecular and suprachoroidal.
  • We are grateful to have a world-class syndicate of investors supporting our efforts to advance these new technologies.
  • With two commercial ready MIGS platforms, Iantrek is uniquely positioned to transform the horizon of micro-interventional ophthalmic surgery.

Alcon Completes Acquisition of Ivantis, Inc., Bringing Hydrus Microstent into Its Global Surgical Portfolio

Retrieved on: 
Monday, January 10, 2022
Medical Supplies, Medical Devices, Health, Surgery, Pharmaceutical, Optical, American Academy, Glaucoma, EEG microstates, Eye, Trabecular meshwork, File, Surgeon, FDA, State, Acquisition, LIBOR, American Academy of Ophthalmology, Sale, Cataract, Retina, CEO, Fellow, Approximation error, Adoption, Disease, University, MIGS, Patient, Mark (given name), Marketing, Social change, Quality of life, Research, NYSE, Intraocular pressure, Vaccine, COVID-19, Compliance, Economy, Growth, Field line, Industry, Adult, Quality control, Forward-looking statement, Aqueous humour, U.S. Securities and Exchange Commission, Pressure, Uncertainty, Risk management, Pharmaceutical industry, Health insurance, Ophthalmology, Alcon, Novartis, Ivanti

It also allows Alcon to begin its future growth plans to bring Hydrus Microstent to more international markets and prioritize its ongoing evidence-based research.

Key Points: 
  • It also allows Alcon to begin its future growth plans to bring Hydrus Microstent to more international markets and prioritize its ongoing evidence-based research.
  • We believe this transaction will further strengthen our global surgical portfolio and help provide a platform for more growth in the glaucoma space, said David Endicott, CEO of Alcon.
  • As we welcome Ivantis associates into Alcon, we look forward to introducing Hydrus Microstent on a broader, global scale in the near future to help even more patients see brilliantly.
  • I am confident that Alcons acquisition of Ivantis will help drive even more research and adoption of Hydrus Microstent.

Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio

Retrieved on: 
Monday, November 8, 2021
Medical Supplies, Medical Devices, Health, Surgery, General Health, Optical, Economy, Social change, Industry, State, COVID-19, Trabecular meshwork, Acquisition, Quality control, Glaucoma, PPP, Uncertainty, Risk, GBS, Foresite Capital, Research, Forward-looking statement, Intention, Severe cognitive impairment, Aqueous humour, Disease, Marketing, Patient, FDA, Quality of life, Compliance, Achievement, Pressure, Eye disease, Eye, CEO, Mark (given name), Cataract, Sale, American Academy, Vaccine, LIBOR, U.S. Securities and Exchange Commission, MIGS, EEG microstates, Retina, Adoption, Ophthalmology, Approximation error, New Enterprise Associates, File, NYSE, Pharmaceutical industry, Risk management

The intended acquisition affirms Alcons commitment to the surgical glaucoma space, further strengthening its industry-leading portfolio across cataract, refractive, retina and glaucoma.

Key Points: 
  • The intended acquisition affirms Alcons commitment to the surgical glaucoma space, further strengthening its industry-leading portfolio across cataract, refractive, retina and glaucoma.
  • This transaction will allow us to add a uniquely effective product into our glaucoma portfolio around the world," said David Endicott, CEO of Alcon.
  • "Our global commercial footprint and development capabilities make us well positioned to build on the success of Ivantis and help even more patients see brilliantly with Hydrus Microstent.
  • Hydrus Microstent was approved by the FDA in August 2018 for use in conjunction with cataract surgery in the United States.

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

Retrieved on: 
Thursday, September 16, 2021
CEO, Health, Patient, Eyelid, EEG microstates, Patent, Adult, District court, NASDAQ, Severe cognitive impairment, MIGS, Duane syndrome, Ivanti, GLOBE, Eye, Intraocular pressure, Sale, Leadership, Method

MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742.

Key Points: 
  • MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742.
  • Sight Sciences complaint seeks an injunction to prevent the infringing manufacture, use and sale of the Hydrus Microstent, along with money damages for past infringement.
  • Since 2006, Sight Sciences has been innovating in circumferential glaucoma surgery (implantable and non-implantable).
  • Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients lives.

Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.

Retrieved on: 
Wednesday, September 15, 2021
Professional Services, Health, Medical Devices, Surgery, Legal, Pharmaceutical, Optical, U.S. Securities and Exchange Commission, Security (finance), Retina, Corporation, Technology, Hydrus, Douglas v. U.S. District Court ex rel Talk America, Marketing, Patient, Glaucoma, EEG microstates, Patent, Cornea, Risk, Clinical trial, NYSE, Glaucoma surgery, District court, GKOS, Growth, MIGS, COVID-19, Ivanti, Southern Division, Cross-link, Compliance, Time, Sale, Central District, Pharmaceutical industry

In accordance with the settlement, the parties will submit a joint request to stay the pending litigation, which had been scheduled for trial beginning on September 28, 2021, and dismiss it upon receipt of the first upfront payment.

Key Points: 
  • In accordance with the settlement, the parties will submit a joint request to stay the pending litigation, which had been scheduled for trial beginning on September 28, 2021, and dismiss it upon receipt of the first upfront payment.
  • Since our founding in 1998, Glaukos has invested considerable time and resources to develop novel technologies that have pioneered an entirely new treatment category for glaucoma surgeons and their patients, said Thomas Burns, Glaukos president and chief executive officer.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.